Across TCGA pan-cancer cohorts, RNU6ATAC11P RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RNU6ATAC11P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RNU6ATAC11P RNA is repressed in tumor relative to normal tissue. In most cancer types RNU6ATAC11P is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and BRCA are the cancer types where RNU6ATAC11P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6ATAC11P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.321	<.001	7	view →
KICH	All	All	−0.390	.001	4	view →
BRCA	All	II,III,IV	+0.057	.037	4	view →
UCEC	All	IV	+0.895	.025	2	view →
LUAD	All	II,III,IV	+0.141	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RNU6ATAC11P RNA expression & survival · all RNU6ATAC11P data types